Annovis Bio Files 8-K

TL;DR

Annovis Bio (ANVS) filed an 8-K on 10/28 for events on 10/26 - material agreement entered.

AI Summary

Annovis Bio, Inc. filed an 8-K on October 28, 2025, reporting on events that occurred on October 26, 2025. The filing indicates the entry into a material definitive agreement and includes financial statements and exhibits. Specific details of the agreement or financial statements are not provided in this excerpt.

Why It Matters

This 8-K filing signals a significant corporate event for Annovis Bio, Inc., potentially involving a new material agreement that could impact its business operations and financial standing.

Risk Assessment

Risk Level: medium — The filing of an 8-K, especially one indicating a material definitive agreement, can introduce uncertainty and potential volatility for the company's stock.

Key Players & Entities

• Annovis Bio, Inc. (company) — Registrant
• October 26, 2025 (date) — Earliest event date
• October 28, 2025 (date) — Filing date
• QR Pharma, Inc. (company) — Former company name

FAQ

Key Financial Figures

• $0.0001 — h registered Common Stock, par value $0.0001 per share ANVS New York Stock Exchang
• $2.05 — ed. The offering price of each Share is $2.05 per share. The gross proceeds to the Co
• $3.425 m — fering are expected to be approximately $3.425 million, before deducting offering expens
• $2.5625 — rcisable and an exercise price equal to $2.5625 per share. The Placement Agent Warrants

Filing Documents

• tm2529544d2_8k.htm (8-K) — 34KB
• tm2529544d2_ex4-1.htm (EX-4.1) — 96KB
• tm2529544d2_ex5-1.htm (EX-5.1) — 14KB
• tm2529544d2_ex10-1.htm (EX-10.1) — 204KB
• tm2529544d2_ex10-2.htm (EX-10.2) — 17KB
• tm2528502d2_ex5-1img01.jpg (GRAPHIC) — 5KB
• 0001104659-25-103254.txt ( ) — 625KB
• anvs-20251026.xsd (EX-101.SCH) — 3KB
• anvs-20251026_lab.xml (EX-101.LAB) — 33KB
• anvs-20251026_pre.xml (EX-101.PRE) — 22KB
• tm2529544d2_8k_htm.xml (XML) — 4KB

01 Entry into a Material Definitive Agreement

Item 1.01 Entry into a Material Definitive Agreement. Registered Direct Offering On October 26, 2025 (the "Agreement Date"), Annovis Bio, Inc. (the "Company") entered into (i) a Securities Purchase Agreement (the "Purchase Agreement"), with the purchasers signatory thereto (the "Purchasers") pursuant to which the Company agreed to issue and sell, in a registered direct offering (the "Offering") an aggregate of 597,561 shares of the Company's common stock, $0.0001 par value per share (the "Common Stock") and (ii) Stock Subscription Agreements (the "Subscription Agreements") with two members of the Board of Directors of the Company pursuant to which they agree to purchase an aggregate of 1,073,171 shares of Common Stock. An aggregate number of 1,670,732 shares of Common Stock (the "Shares") will be issued. The offering price of each Share is $2.05 per share. The gross proceeds to the Company from the Offering are expected to be approximately $3.425 million, before deducting offering expenses payable by the Company. The Offering is expected to close on or about October 28, 2025 (the "Closing Date"), subject to the satisfaction of customary closing conditions. The Company currently plans to use the net proceeds from the Offering, for the continued clinical development of the Company's lead compound Buntanetap in a Phase 3 study for Alzheimer's disease, and for working capital and general corporate purposes. The Purchase Agreement and the Subscription Agreements contain customary representations, warranties and agreements by the Company, customary conditions to closing, indemnification obligations of the Company, including for liabilities arising under the Securities Act of 1933, as amended (the "Securities Act"), other obligations of the parties and termination provisions. The representations, warranties and covenants contained in the Purchase Agreement and the Subscription Agreement were made only for the purposes of such agreement and as of the specific dates, w

01 Other Events

Item 8.01 Other Events. In connection with the filing of the Prospectus Supplement, the Company is filing a legal opinion of its counsel, Loeb & Loeb LLP, regarding the validity of the Shares, the Placement Agent Warrant, and the shares underlying the Placement Agent Warrants being registered, which opinion is attached hereto as Exhibit 5.1 and is incorporated herein by reference.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits Exhibit Number Description 4.1 Form of Placement Agent Warrant 5.1 Opinion of Loeb & Loeb LLP 10.1 Securities Purchase Agreement, dated October 26, 2025 10.2 Form of Stock Subscription Agreement with Directors 23.1 Consent of Loeb & Loeb LLP (contained in Exhibit 5.1) 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ANNOVIS BIO, INC. Date: October 28, 2025 By: /s/ Maria Maccecchini Name: Maria Maccecchini Title: President and Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR